The Claim

In hepatocytes isolated from KKAy mice, treatment with the mTOR inhibitor rapamycin increases the proportion of LTR-positive autolysosomes and reduces the accumulation of p62, which correlates with upregulated expression of V-ATPase subunits, suggesting that mTOR inhibition enhances autophagic flux in the context of hepatic steatosis.

Source: Inhibition of mTOR improves the impairment of acidification in autophagic vesicles caused by hepatic steatosis.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
10score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

How it works
1 study reviewed
In plain English

Treating liver cells from diabetic mice with a drug called rapamycin seems to boost their waste-cleaning process, which might help clear fat buildup in the liver.

See the scientific wording

Incubation with the mTOR inhibitor rapamycin increases the proportion of LTR-positive autolysosomes and reduces p62 accumulation in hepatocytes from KKAy mice, correlating with increased expression of V-ATPase subunits, suggesting mTOR inhibition may improve autophagic flux in hepatic steatosis.

What the research says

1 study

  1. Study: Inhibition of mTOR improves the impairment of acidification in autophagic vesicles caused by hepatic steatosis.

    The study shows that treating fatty liver cells from mice with rapamycin helps clean up cellular waste more effectively, which matches what the claim says.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.